The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial
暂无分享,去创建一个
Y. Chao | Y. Chung | Jijin Yang | G. Han | Jianhua Wang | Teng‐Yu Lee | Guo-Liang Shao | B. Kim | J. Yoon | Jung‐Hwan Yoon